Church & Dwight's e-commerce sales surge 20% in Q3, driven by digitally oriented acquisitions, online market-share gains and investments in AI capabilities.
Church & Dwight keeps finding new things to sell consumers, including mouthwash packets that fit in a pocket. Sherwin-Williams is winning over the pros who repaint America's homes, even while the housing market drags.
Danske Bank A S decreased its stake in shares of Church and Dwight Co., Inc. (NYSE: CHD) by 41.4% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 91,229 shares of the company's stock after selling 64,408 shares during the quarter. Danske
EWING, N.J.--(BUSINESS WIRE)--Church & Dwight Co., Inc. (NYSE: CHD) has signed a definitive agreement to acquire 45% of the shares of BALI Treatment GmbH, a rapidly growing hair care and styling company in Europe that includes the BALI CURLS™ and BALI GENTS™ brands, for approximately $225 million. The brands have established market leading positions in Germany and Austria with expansion across Europe now underway. The company reported net sales for the twelve months ended October 31, 2026,.
Eurizon Capital SGR S.p.A. raised its position in Church and Dwight Co., Inc. (NYSE: CHD) by 99.2% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 211,142 shares of the company's stock after buying an additional 105,148
Church and Dwight Co., Inc. (NYSE: CHD - Get Free Report) EVP Surabhi Pokhriyal sold 21,970 shares of the firm's stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $111.23, for a total value of $2,443,723.10. Following the sale, the executive vice president directly owned 896 shares in
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial evaluating monthly subcutaneous adminis
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced new, expanded data from the Phase 2 SOLSTICE trial evaluating monthly subcutaneous administration of eleb